• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Autoantibody Profiling and Machine Learning Improves Early Esophageal Cancer Detection

by
November 16, 2026
in Health
Reading Time: 5 mins read
0
Autoantibody Profiling and Machine Learning Improves Early Esophageal Cancer Detection

Autoantibody Profiling and Machine Learning Improves Early Esophageal Cancer Detection

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Esophageal squamous cell carcinoma (ESCC) is a deadly malignancy that currently poses a significant global health burden, particularly in Eastern Asia. A primary clinical challenge in addressing this cancer is its frequently asymptomatic presentation during the early stages, which results in the majority of patients being diagnosed at advanced stages when the five-year survival rate drops below 30 percent. While endoscopy with biopsy remains the clinical gold standard for diagnosis, it is inherently invasive, costly, and difficult to deploy for large-scale population screening. To address these critical limitations, researchers have sought to identify non-invasive, accurate biomarkers. A new study has now demonstrated that plasma autoantibody profiling, enabled by phage immunoprecipitation sequencing (PhIP-seq) and refined through integrated machine learning algorithms, can provide a robust diagnostic framework for the early detection and management of ESCC.

Tumor-associated autoantibodies (TAAbs) offer a promising avenue for non-invasive cancer diagnostics. These antibodies are produced by the humoral immune system in response to aberrant antigens expressed by tumor cells, arising from processes like oncogene activation, protein misfolding, and genomic instability. Unlike traditional biomarkers such as circulating tumor DNA or carcinoembryonic antigen, TAAbs are highly stable in serum and can potentially be detected years before the onset of clinical symptoms, offering a vital window for early diagnosis. However, previous attempts to use TAAbs as diagnostic tools have often been limited by the use of pre-selected antigen panels and a lack of robust validation in independent populations. The PhIP-seq technology overcomes these hurdles by providing an unbiased, high-throughput platform that comprehensively maps the serum antibody repertoire against hundreds of thousands of peptides covering the entire human proteome.

In the present study, the researchers established a large, multi-center cohort comprising 1039 plasma samples collected from three hospitals to systematically profile the autoantibody repertoire in ESCC. Following rigorous quality control of the PhIP-seq library construction and sequencing process, the samples were stratified into a training set, an internal validation set, and two independent external validation sets, including a nested case-control cohort with pre-diagnostic samples. This multi-center design allowed the team to not only identify potential diagnostic markers but also validate the generalizability of their models across different clinical environments. The study confirmed high technical reproducibility of the assay, with mean intra-sample correlations significantly greater than inter-sample correlations, and a mean mapping accuracy of approximately 90.4 percent at the target sequencing depth.

To transition from high-dimensional PhIP-seq data to a reliable diagnostic tool, the researchers employed a rigorous feature selection workflow within the training set, intentionally designed to prevent data leakage. They initially identified 1137 differential peptides through comparison between ESCC patients and normal controls, using a significance threshold of P < 0.05 and a log2-fold change greater than 0.585. To derive a robust and parsimonious diagnostic signature, they applied three complementary feature selection methods—LASSO regression, the Boruta algorithm, and Recursive Feature Elimination (RFE)—to this initial pool. The intersection of these distinct methods distilled a final panel of 18 core peptides, which corresponded to 16 genes. Among these, genes such as INPP4B, MCM3AP, APEX2, and QTRT1 had not been previously reported in the context of ESCC autoantibody research, representing novel candidate biomarkers.

The study then evaluated eight different machine learning models using these 18 core features, ultimately selecting the eXtreme Gradient Boosting (XGBoost) model, which demonstrated the most robust and consistent performance across the diverse validation sets. The XGBoost model achieved an area under the receiver operating characteristic curve (AUC) of 0.912 in the training set, 0.782 in the internal validation set, and 0.809 in the first external validation set. Decision curve analysis indicated that the model provided a higher clinical net benefit than default clinical strategies across most reasonable risk thresholds. The classification results highlighted the model’s ability to discriminate ESCC patients from normal controls with high performance, confirming that the 18-peptide signature captures stable diagnostic information superior to single antigens like p53, which were excluded during the stringent machine learning feature selection process.

One of the most significant findings of this work concerns the potential for early risk prediction. In the nested case-control cohort, which constituted the second external validation set, the model achieved an AUC of 0.729. Furthermore, when analyzing a subset of 157 ESCC patients with definitive clinical staging, the model showed superior diagnostic efficacy for early-stage ESCC, achieving an AUC of 0.931 for stage I–II patients, compared to 0.856 for stage III and 0.874 for stage IV. These results suggest that the identified autoantibody signals are present in the bloodstream long before the appearance of clinical symptoms, providing a viable technical pathway for early screening, although the study authors emphasized that their model is intended for high-risk populations rather than mass screening of the general asymptomatic population.

To interpret the performance of the XGBoost model and identify the biological drivers of its predictions, the researchers utilized SHAP (SHapley Additive exPlanations) analysis. The SHAP summary plots revealed that peptides corresponding to KMT2C, INPP4B, and MCM3AP were the most significant contributors to the model’s diagnostic accuracy. These antigens are known key players in cancer biology; for instance, KMT2C is a critical epigenetic regulator frequently mutated in various cancers, and INPP4B acts as a negative regulator of the PI3K-Akt survival signaling pathway. Additionally, the inclusion of multiple peptides mapping to distinct regions of CTAG1A (NY-ESO-1) demonstrated the value of capturing diverse epitope responses against a single immunogenic target. These associations suggest that the model is capturing genuine biological signals related to tumorigenesis and genomic instability, rather than overfitting to noise.

The study also explored the model’s utility in assessing treatment response. By comparing the autoantibody repertoires of patients before and after radical chemoradiotherapy, the researchers identified significant shifts in pathways related to inorganic ion homeostasis, extracellular matrix organization, and chromatin remodeling. Interestingly, two peptides—PDE8B and PHRF1—appeared in both the diagnostic signature and the differential analysis of treatment response. PDE8B, which regulates cAMP levels, and PHRF1, a positive regulator of TGF-β signaling, showed potential as candidate biomarkers with dual utility for diagnosis and efficacy monitoring. While the majority of post-treatment patients continued to test positive, likely reflecting residual disease or ongoing immune activation, these findings provide a preliminary framework for developing tools to monitor patient response to therapy.

Despite these promising results, the researchers acknowledged several limitations inherent to the study. The sample size of the nested case-control cohort was relatively small, which may affect the long-term stability of the model’s evaluation. Furthermore, while the analytical framework was designed to distill a robust signature, the initial discovery phase relied on unadjusted P-values, necessitating future validation through alternative platforms such as ELISA. Another limitation is that all normal controls in the external validation cohorts were obtained from a single hospital, raising potential concerns about whether the model might learn location-specific factors rather than universal biological markers. Finally, the PhIP-seq technology itself has limitations in capturing conformational epitopes, as it primarily profiles linear peptides. Future research will need to employ complementary technologies, such as membrane-integrated proteome arrays or recombinant epitope arrays, to profile autoantibodies against native protein conformations missed by PhIP-seq.

In conclusion, this research presents an 18-peptide autoantibody signature integrated within an XGBoost diagnostic model that offers a powerful and robust approach for the early detection of ESCC. The findings demonstrate stable diagnostic performance across multi-center and nested case-control cohorts, highlighting the potential of the model for clinical application in risk stratification and early screening. While the study provides a significant advancement over cross-sectional case-control designs by offering prospective validation evidence, the researchers emphasized that the next essential steps involve testing the identified biomarkers in larger, independent prospective cohorts and confirming the results across diverse clinical settings to establish their clinical utility and generalizability for esophageal cancer management.

Subject of Research: Diagnostic application of PhIP-seq autoantibody profiling and machine learning for esophageal squamous cell carcinoma

Article Title: Plasma autoantibody profiling via PhIP-seq and machine learning for diagnosis of esophageal squamous cell carcinoma

Article References: Jin, M.-J., Xu, Y.-W., He, X.-X., Ma, M.-L., Wu, W.-Z., Zhang, J.-F., Pan, D.-Y., Chen, S.-X., Wang, G., Huang, Q.-F., Chen, S.-Z., Huang, H.-C., Peng, Y.-H., Tao, S.-C., Li, Y., Li, E.-M., & Xu, L.-Y. (2026). Plasma autoantibody profiling via PhIP-seq and machine learning for diagnosis of esophageal squamous cell carcinoma. Nature Communications, 17(1), Article 10855. https://doi.org/10.1038/s41467-026-77855-9

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77855-9

Keywords: Esophageal Squamous Cell Carcinoma, PhIP-seq, Autoantibodies, Machine Learning, XGBoost, Early Detection, Biomarkers, SHAP Analysis, Liquid Biopsy, Oncology, Proteomics, Cancer Screening, KMT2C, INPP4B, CTAG1A, Precision Medicine, Immunology

News Source: Nathaniel Bowman. (November 16, 2026). Autoantibody Profiling and Machine Learning Improves Early Esophageal Cancer Detection. Scienmag.

Tags: Autoantibodiesbiomarkerscancer screeningCTAG1AEarly DetectionEsophageal squamous cell carcinomaimmunologyINPP4BKMT2CLiquid BiopsyMachine LearningOncologyPhIP-seqPrecision MedicineProteomicsSHAP analysisXGBoost
Share12Tweet7Share2ShareShareShare1

Related Posts

Overweight Exceeds Thinness Among Secondary School Students in Sierra Leone

Overweight Exceeds Thinness Among Secondary School Students in Sierra Leone

November 18, 2026
MRI Features Identify Fracture-Dislocation Patterns in Schatzker Type IV Tibial Plateau Fractures

MRI Features Identify Fracture-Dislocation Patterns in Schatzker Type IV Tibial Plateau Fractures

November 18, 2026

Keloids and Hypertrophic Scars Share Matrix Programmes Despite Divergent Spatial Distributions

November 18, 2026

Shortened Frontal Assessment Battery Effectively Detects Executive Dysfunction in Neurodegenerative Disorders

November 18, 2026

POPULAR NEWS

  • Delayed Corticosteroids Linked to Improved Survival in Deteriorating Septic Shock Phenotype

    Delayed Corticosteroids Linked to Improved Survival in Deteriorating Septic Shock Phenotype

    29 shares
    Share 12 Tweet 7
  • NLRP1 Inhibition Reduces Inflammation in Familial Mediterranean Fever Cellular Models

    29 shares
    Share 12 Tweet 7
  • New Framework Refines Echocardiographic Guidance for Complex Transcatheter Mitral Valve Procedures

    29 shares
    Share 12 Tweet 7
  • Pied Kingfisher Optimization Enhances Dynamic Stability In Simulated Wave Energy Conversion Systems

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Lactobacillus Rhamnosus Promotes Abdominal Fat Deposition in Mice Without Changing Body Weight

Overweight Exceeds Thinness Among Secondary School Students in Sierra Leone

MRI Features Identify Fracture-Dislocation Patterns in Schatzker Type IV Tibial Plateau Fractures

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.